Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2009

Sigma-Aldrich Purchases NextGen’s Electrophoresis Franchise

  • NextGen Sciences divested its electrophoresis business to Sigma-Aldrich for an up-front fee and royalties for three years. This completes NextGen’s realignment to a biomarker services business.

    Under the deal with Sigma-Aldrich, NextGen has sold its automated gel casting unit called a2DEoptimizer™ and the range of large format precast gels known as optigels™. Sigma-Aldrich will focus primarily on the supply of optigels, initially to the North American and European markets.

    In December 2008, NextGen sold its gene-to-protein automation and software business to eXeTek, a spinout led by two former NextGen employees. NextGen also acquired a 24% stake in eXeTek at the time and will receive 5% royalties for three years.

    Launched in November 2007, NextGen Sciences’ service portfolio called biomarkerexpress™ includes biomarker discovery, assay development, and testing.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »